These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9037269)

  • 21. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients.
    Limaye AP
    Semin Respir Infect; 2002 Dec; 17(4):265-73. PubMed ID: 12497543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune globulin versus antivirals versus combination for prevention of cytomegalovirus disease in transplant recipients.
    King SM
    Antiviral Res; 1999 Jan; 40(3):115-37. PubMed ID: 10027647
    [No Abstract]   [Full Text] [Related]  

  • 24. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007.
    Griffiths P; Whitley R; Snydman DR; Singh N; Boeckh M;
    Herpes; 2008 Oct; 15(1):4-12. PubMed ID: 18983762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral strategies to combat cytomegalovirus infections in transplant recipients.
    Lischka P; Zimmermann H
    Curr Opin Pharmacol; 2008 Oct; 8(5):541-8. PubMed ID: 18662804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical aspects and management of cytomegalovirus infection.
    Sissons JG; Carmichael AJ
    J Infect; 2002 Feb; 44(2):78-83. PubMed ID: 12076065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytomegalovirus prophylaxis in solid organ transplant recipients.
    Patel R; Snydman DR; Rubin RH; Ho M; Pescovitz M; Martin M; Paya CV
    Transplantation; 1996 May; 61(9):1279-89. PubMed ID: 8629285
    [No Abstract]   [Full Text] [Related]  

  • 30. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.
    Ruttmann E; Geltner C; Bucher B; Ulmer H; Höfer D; Hangler HB; Semsroth S; Margreiter R; Laufer G; Müller LC
    Transplantation; 2006 May; 81(10):1415-20. PubMed ID: 16732179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of antiviral prophylaxis in renal transplant recipients at high risk of cytomegalovirus infection.
    Costa C; Bergallo M; Cavallo R
    J Clin Virol; 2008 Jul; 42(3):293-4. PubMed ID: 18403256
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
    Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
    Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delayed occurrence of cytomegalovirus disease in organ transplant recipients receiving antiviral prophylaxis: are we winning the battle only to lose the war?
    Singh N
    Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):643-6. PubMed ID: 12373496
    [No Abstract]   [Full Text] [Related]  

  • 34. Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients.
    Wittes JT; Kelly A; Plante KM
    Transplant Proc; 1996 Dec; 28(6 Suppl 2):17-24. PubMed ID: 9037273
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
    Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
    J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.
    Legendre C; Pascual M
    Clin Infect Dis; 2008 Mar; 46(5):732-40. PubMed ID: 18220478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients.
    Lurain NS; Bhorade SM; Pursell KJ; Avery RK; Yeldandi VV; Isada CM; Robert ES; Kohn DJ; Arens MQ; Garrity ER; Taege AJ; Mullen MG; Todd KM; Bremer JW; Yen-Lieberman B
    J Infect Dis; 2002 Sep; 186(6):760-8. PubMed ID: 12198609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients--a meta-analysis.
    Snydman DR
    Clin Transplant; 1995 Dec; 9(6):490-1. PubMed ID: 8645893
    [No Abstract]   [Full Text] [Related]  

  • 39. A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial.
    Snydman DR; Werner BG; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS; Strom TB; Carpenter CB
    Transplant Proc; 1988 Dec; 20(6 Suppl 8):24-30. PubMed ID: 2849222
    [No Abstract]   [Full Text] [Related]  

  • 40. Cytomegalovirus prophylaxis in solid organ transplant recipients: the issues.
    Legendre C; Thervet E
    Transplant Proc; 2000 Mar; 32(2):377-8. PubMed ID: 10715444
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.